vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 11 2025
0mins
Source: Globenewswire
Company Announcement: vTv Therapeutics Inc. will participate in the H.C. Wainwright “HCW@Home” Series on June 12, 2025, discussing their lead product cadisegliatin, an oral therapy for type 1 diabetes.
Company Overview: vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral drug candidates for diabetes and chronic diseases, with cadisegliatin currently in Phase 3 trials.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
